The CCR5Delta32 allele slows disease progression of human immunodeficiency virus-1-infected children receiving antiretroviral treatment.
The role of the CCR5Delta32 allele in human immunodeficiency virus (HIV)-1-related disease progression was analyzed for 457 antiretroviral-naïve children who had participated in the Pediatric AIDS Clinical Trials Group 152 study, which demonstrated that didanosine (ddI) or zidovudine + ddI treatments were superior to zidovudine alone. The CCR5Delta32 allele was detected at an overall frequency of 6.1% (28/457). At study entry, heterozygote children (wild type [wt]/Delta32) had higher baseline median CD4(+) counts/mm(3) than wt/wt children had (1035 vs. 835 cells/mm(3); P=. 043), higher mean weight-for-age Z scores (-0.15 vs. -0.84; P=.01), and a trend toward less cortical atrophy (P=.059). During antiretroviral treatment and study follow-up, there was a trend toward less disease progression and death among heterozygote children than among wt/wt children (P=.056; relative hazard, 0.28; 95% confidence interval, 0.07-1.13) independent of the antiretroviral treatment to which they were randomized.
Department of Pediatrics, University of California San Diego, La Jolla, CA 92093-0672, USA.
C F
CF
Barroga
C
C
Raskino
M C
MC
Fangon
P E
PE
Palumbo
C J
CJ
Baker
J A
JA
Englund
S A
SA
Spector
D000483:Alleles; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D016049:Didanosine / Q000627:therapeutic use; D018450:Disease Progression; D018572:Disease-Free Survival; D005006:Ethnicity; D005787:Gene Frequency; D015658:HIV Infections / Q000188:drug therapy* / Q000401:mortality*; D015497:HIV-1; D006801:Humans; D044469:Racial Groups; D019713:Receptors, CCR5 / Q000235:genetics*; D017384:Sequence Deletion; D015215:Zidovudine / Q000627:therapeutic use
D019380:Anti-HIV Agents; D019713:Receptors, CCR5; D015215:Zidovudine; D016049:Didanosine